SCHEMBL509551

SCHEMBL509551

COc1cc(-c2cc3cc(C)ccc3c(N)n2)cc(OC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.52
DHFR P00374 1/20 0.46
KDM4E B2RXH2 2/20 0.43
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
ADORA3 P0DMS8 2/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
MAOB P27338 1/20 0.43
PDGFRB P09619 1/20 0.43
NEK2 P51955 3/20 0.42
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
BRD4 O60885 1/20 0.41
FYN P06241 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509201 0.89 RAD52 (0.49) RAD52DHFRKDM4ETSHRPOLB
SCHEMBL509771 0.86 KDM4E (0.52) RAD52DHFRKDM4ETSHRADORA2A
SCHEMBL509491 0.83 NPC1 (0.43) RAD52KDM4ETSHRADORA3ADORA2A
SCHEMBL508360 0.80 SYK (0.56) KDM4EPOLBADORA1MEN1MAPT
SCHEMBL509564 0.79 ADORA2A (0.47) KDM4ETSHRPOLBADORA2AADORA1
SCHEMBL509907 0.78 HSP90AA1 (0.56) RAD52DHFRKDM4EPOLBADORA3
SCHEMBL509538 0.77 SCN2A (0.48) KDM4EADORA3ADORA2AADORA1MAOB
SCHEMBL510204 0.75 RAD52 (0.49) RAD52DHFRKDM4ETSHRADORA2A
SCHEMBL509539 0.75 XDH (0.50) KDM4EADORA2AADORA1MEN1CYP1A2
SCHEMBL3831804 0.74 NPC1 (0.54) MAOBBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532020-B 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives REXAHN PHARMACEUTICALS INC 2015-02-25 CN disclosed
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 RAD52 542/4885DHFR 178/4885KDM4E 2109/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 RAD52 542/4885DHFR 178/4885KDM4E 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.